Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)

Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target.

The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naive to anti-immunoglobulin-E (IgE) therapy for CSU”.

Management reported that Sanofi and Regeneron’s Dupixent can be used as a first-line targeted treatment option, and attained approval as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria.

Sanofi (NASDAQ:SNY) added that the approval was based on phase 3 studies that demonstrated a significant reduction in itch and hives at 24 weeks compared to placebo due to Dupixent.

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.